Furthermore, Treg hamper anti-tumor immunity via the interaction of CTLA-4 with the co-stimulatory receptors CD80 and CD86, which are expressed by APC-like DC, resulting in the inhibition of their T cell stimulatory capacity [130,147]. The gene discussed is CTLA4; the disease is neoplasm.